Gladius Capital Management LP Gilead Sciences, Inc. Transaction History

Gladius Capital Management LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$73.27 - $83.09 $30,626 - $34,731	418 New	418 $33,000
Q2 2023 Dec 18, 2023	BUY	$76.01 - $86.7 $32,076 - $36,587	422 New	422 $32,000
Q2 2023 Aug 08, 2023	BUY	$76.01 - $86.7 $32,076 - $36,587	422 New	422 $33,000
Q2 2022 Aug 10, 2022	SELL	$57.72 - $65.01 $17.6 Million - $19.8 Million	-304,851 Reduced 99.26%	2,266 $141,000
Q1 2022 Apr 29, 2022	BUY	$57.92 - $72.58 $17.7 Million - $22.2 Million	305,590 Added 20012.44%	307,117 $18.3 Million
Q4 2021 Feb 08, 2022	BUY	$64.88 - $73.64 $99,071 - $112,448	1,527 New	1,527 $111,000
Q1 2020 May 07, 2020	SELL	$62.63 - $80.22 $251,897 - $322,644	-4,022 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$61.62 - $67.78 $211,726 - $232,892	-3,436 Reduced 46.07%	4,022 $262,000
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $122,707 - $135,447	1,963 Added 35.72%	7,458 $473,000
Q2 2019 Aug 13, 2019	SELL	$61.87 - $69.38 $766,198 - $859,201	-12,384 Reduced 69.27%	5,495 $373,000
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $364,737 - $408,601	5,833 Added 48.42%	17,879 $0
Q4 2018 Feb 15, 2019	BUY	$60.54 - $79.0 $729,264 - $951,634	12,046 New	12,046 $753,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.